Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-641P is a *processed pseudogene*—a DNA segment that closely resembles the U6 small nuclear RNA gene, originally functional in RNA splicing as part of the spliceosome, but which now lacks a functional promoter or regulatory regions[6][4]. As a pseudogene, it is not transcribed or translated and does not encode functional protein or RNA. U6 snRNA itself is essential for pre-mRNA splicing in the nucleus, but pseudogenes such as RNU6-641P accumulate in the genome, typically as a result of retrotransposition[6][1]. These sequences are common backups found in vertebrate genomes, reflecting evolutionary history rather than active biological function[5][6][4]. There is no evidence that RNU6-641P or similar U6 pseudogenes are involved in disease, can serve as therapeutic targets, interact with drugs, act as biomarkers, or pose safety concerns. The listing is considered incorrect in the context of drug, therapeutic, or receptor target databases, as pseudogenes like RNU6-641P are not considered actionable molecular targets or functional biomolecules[6][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 641, pseudogene (RNU6-641P).